Date:5/3/2011

red income taxes(60,845)(16,361)   Sub-total268,081235,578   Changes in operating assets and liabilities, net of asset and businessacquisitions Accounts receivable(104,197)(13,039)Inventories(31,304)(33,706)Income taxes refundable12,4693,694Accounts payable15,521(13,303)Payroll and related taxes(9,072)24,521Accrued customer programs31,770(1,005)Accrued liabilities(10,739)(7,731)Accrued income taxes47,07724,972Other9,428439   Sub-total(39,047)(15,158)Net cash from operating activities229,034220,420Cash Flows (For) From Investing Activities   Proceeds from sales of securities560-   (Return of) Proceeds from sale of business(3,558)35,980   Acquisitions of businesses, net of cash acquired2,624(58,885)   Acquired research and development-(14,000)   Acquisitions of assets(10,000)(10,262)   Additions to property and equipment(46,542)(34,545)Net cash for investing activities(56,916)(81,712)Cash Flows (For) From Financing Activities   Repayments of short-term debt, net(7,820)-   Borrowings of long-term debt150,442-   Repayments of long-term debt(195,000)(67,771)   Deferred financing fees(5,158)(3,500)   Excess tax benefit of stock transactions16,2565,730   Issuance of common stock12,47614,593   Repurchase of common stock(8,285)(70,972)   Cash dividends(18,779)(16,566)Net cash for financing activities(55,868)(138,486)Effect of exchange rate changes on cash(2,778)658Net increase in cash and cash equivalents113,472880Cash and cash equivalents of continuing operations, beginning of period109,765317,638Cash balance of discontinued operations, beginning of period-4Cash and cash equivalents, end of period223,237318,522Less cash balance of discontinued operations, end of period--Cash and cash equivalents of continuing operations, end of period

$

223,237$

318,522Supplemental Disclosures of Cash Flow Information   Cash paid/received during the period for:Interest paid

'/>"/>

SOURCE Perrigo Company Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine technology :

1. Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Mens Rogaine® Foam
2. Perrigo Company Announces Quarterly Dividend
3. Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
4. Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets
5. Perrigo Announces Conclusion of the FDA Re-Inspection
6. Perrigo Company to Present at the Barclays Capital 2011 Global Health Care Conference
7. Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter
8. Perrigo Company to Present at the Citi 2011 Global Health Care Conference
9. Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma
10. Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products
11. Perrigo Announces Settlement of Rogaine® Foam Patent Litigation